Health
AI Tool Could Help Target Prostate Cancer Treatment, Improve Patient Outcomes
A new artificial intelligence (AI) tool could significantly improve outcomes for prostate cancer patients by identifying who would benefit most from the drug abiraterone, according to UK researchers presenting their findings at the American Society of Clinical Oncology’s annual meeting this week.
The tool analyzes tumour biopsy images to detect hidden biomarkers that predict whether a patient is likely to respond well to abiraterone, a drug known to nearly halve the risk of death for some men with prostate cancer. While effective, abiraterone is expensive and carries potential side effects such as high blood pressure, liver issues, and diabetes. These concerns have led health systems to prescribe it cautiously.
“This research shows that we can pick out the people who will respond best to abiraterone, and those who will do well from standard treatment alone – hormone therapy and radiotherapy,” said Professor Nick James, co-lead of the study from the UK’s Institute of Cancer Research.
The AI model was developed by studying tumour pathology slides and identifying molecular markers invisible to the human eye. Researchers then applied the tool to biopsy images from over 1,000 men enrolled in an earlier clinical trial on prostate cancer therapies.
Among patients whose tumours tested positive for the biomarker, abiraterone cut the five-year mortality rate from 17% to 9%. In contrast, those without the biomarker did not show a significant benefit from the drug, suggesting they could avoid unnecessary side effects and rely on standard treatments instead.
“This study shows, in a very large cohort of patients, that novel algorithms can be used to extract information from routinely available pathology slides to tailor these treatments to specific patients and minimise over-treatment whilst maximising the chance of cure,” said Professor Gert Attard of the University College London Cancer Institute, the study’s co-lead.
In the UK, access to abiraterone varies. While it is approved for use in newly diagnosed high-risk patients in Scotland and Wales, England’s NHS only offers the drug once the cancer has spread. The researchers called for policy changes, estimating that up to 8,400 men in England could benefit from earlier access.
“Access to this life-extending drug is currently a postcode lottery,” James said. “Those living in Scotland and Wales can receive the treatment for free — others cannot.”
Prostate cancer remains one of the most common cancers among men, with nearly 336,000 new cases diagnosed annually in the European Union.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
